Pasithea Therapeutics Corp. Quarterly report pursuant to Section 13 or 15(d)

Stock Options (Tables)

3 Months Ended

Mar. 31, 2023

	Number of Options		Weighted average exercise price per share		Weighted average remaining contractual term (years)		Aggregate intrinsic value (in thousands)
Outstanding, January 1, 2023		1,300,000	$	2.28		9.12	$	-
Granted		880,000		0.49		9.91		-
Expired/Cancelled		-		-		-		-
Exercised		-		-		-		-
Outstanding, March 31, 2023		2,180,000	$	1.56		9.29		-

Exercisable, March 31, 2023		233,334	$	4.37		8.48	$	-